8-K: Terns Pharmaceuticals Announces Positive Phase 1 Results for Oral GLP-1R Agonist TERN-601 in Obesity Treatment

Terns Pharmaceuticals reports positive top-line data from its Phase 1 trial of TERN-601, showing significant weight loss and good tolerability in obese and overweight adults.

Summary

• Terns Pharmaceuticals announced positive results from its Phase 1 clinical trial for TERN-601, an oral GLP-1R agonist.
• The trial was a randomized, double-blind, placebo-controlled study in healthy adults with obesity or overweight.
• The study included single and multiple ascending doses (SAD and MAD) of TERN-601.
• The 28-day MAD study showed a maximum placebo-adjusted mean weight loss of 4.9% at the highest dose of 740 mg QD.
• 67% of participants at the top dose lost 5% or more of their baseline body weight.
• TERN-601 was well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations.
• The majority of adverse events were mild, with gastrointestinal events being mild to moderate and consistent with the GLP-1R agonist class.
• There were no clinically meaningful changes in liver enzymes, vital signs, or electrocardiograms.
• Terns plans to advance TERN-601 into Phase 2 clinical development in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive results from a Phase 1 trial, with strong efficacy and tolerability data. The company's plans to move into Phase 2 are also encouraging. The sentiment is very positive from an investment perspective.

Positives

• The study showed statistically significant weight loss with TERN-601.
• The drug was well-tolerated, even with rapid dose titration.
• TERN-601 has properties that may allow for sustained target coverage and a flat PK curve.
• The company has identified an optimal range of clinically active, well-tolerated doses for Phase 2 trials.
• The results support the potential of TERN-601 as a monotherapy or in combination with other agents for obesity treatment.

Negatives

• Some participants experienced mild to moderate gastrointestinal adverse events, which are consistent with the GLP-1R agonist class.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to vary materially.
• There are risks associated with the initiation, cost, timing, progress, and results of the company's research and development activities and clinical trials.
• The company's future success depends on the successful development and commercialization of its product candidates.

Future Outlook

Terns plans to advance TERN-601 into Phase 2 clinical development in 2025 and believes it has identified an optimal range of clinically active, well-tolerated doses to take forward.

Management Comments

• Amy Burroughs, chief executive officer of Terns, stated that the results underscore TERN-601's potential to be a class-leading GLP-1R agonist.
• Emil Kuriakose, chief medical officer of Terns, noted that TERN-601's distinct drug properties allowed for sustained target coverage with once-daily dosing and the evaluation of doses up to 740 mg, while being tolerable.

Industry Context

The announcement is significant in the context of the growing market for obesity treatments, particularly GLP-1 receptor agonists. The positive results position TERN-601 as a potential competitor in this space.

Comparison to Industry Standards

• The 4.9% placebo-adjusted weight loss at the highest dose is competitive with other GLP-1R agonists in early-stage development.
• The tolerability profile, with no treatment-related discontinuations, is a positive differentiator compared to some other drugs in the class.
• The company's focus on oral administration is also a potential advantage over injectable GLP-1R agonists.
• Companies like Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy, Ozempic) have set high benchmarks for efficacy and safety in the GLP-1 space, and Terns will need to demonstrate similar or better results in Phase 2 and 3 trials to compete effectively.

Stakeholder Impact

• Shareholders will likely view the positive trial results favorably.
• Employees may be motivated by the progress of the company's pipeline.
• Patients with obesity may benefit from the development of a new treatment option.
• The results could attract potential partners or investors.

Next Steps

• Terns plans to advance TERN-601 into Phase 2 clinical development in 2025.
• The company plans to submit data from this clinical trial for presentation at an upcoming scientific conference.

Key Dates

Keywords

TERN-601, GLP-1R agonist, obesity, weight loss, clinical trial, Phase 1, pharmacokinetics, pharmacodynamics, tolerability, Terns Pharmaceuticals